Journal of Blood & Lymph

Charles Bruker

Publications

• Case Report
  Romiplostim as a Viable and Long-term Remedy for Refractory Immune Thrombocytopenia and Concomitant Small B-Cell Lymphoma
  Author(s): Germame Ajebo, Paul Dainer, Jeremy Pantin, Nathan Ryan and Charles BrukerGermame Ajebo, Paul Dainer, Jeremy Pantin, Nathan Ryan and Charles Bruker
  
  Immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by immune-mediated destruction of otherwise normal platelets and can be either primary, without obvious initiating or underlying cause, or secondary ITP due to an underlying disease or drug exposure. The goals of therapy for ITP include achieving an adequate platelet level for hemostasis and minimizing toxicities with current options including: corticosteroids, rituximab, splenectomy, intravenous gamma globulin (IVIG), Anti-D, and thrombopoietin receptor agonists (TPO) like romiplostim and eltrombopag. TPO mimetics like romiplostim have emerged as viable and practical option in relapsed and refractory ITP. We present a 70-year-old Caucasian male patient with chronic lymphocytic leukemia/small cell lymphoma (CLL/SLL) related secondary ITP who had been maintained for nearly a decade on rom.. Read More»
  DOI: 10.37421/jbl.2019.9.236

  Abstract PDF